JW Pharmaceutical Valuation

Q: What is the Fair Price of A001067 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

A001067 (₩58800) is trading below our estimate of [[fair value]] (₩164854.86)

Is A001067 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A001067 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A001067 (₩58800) is trading below our estimate of fair value (₩164854.86)

Significantly Below Fair Value: A001067 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A001067?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for A001067. This is calculated by dividing A001067's market cap by their current preferred multiple.
What is A001067's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	₩706.12b

A001067 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1x
Enterprise Value/EBITDA	6.6x
PEG Ratio	0.7x

Price to Earnings Ratio vs Peers

How does A001067's PE Ratio compare to its peers?

The above table shows the PE ratio for A001067 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	16.9x
A086450 DongKook Pharmaceutical	13.9x	14.2%	₩757.6b
A000640 Dong-A Socio Holdings	14.8x	n/a	₩755.1b
A003850 Boryung	11.2x	9.9%	₩720.6b
A214370 Caregen	27.9x	14.1%	₩945.3b
A001067 JW Pharmaceutical	20.2x	29.4%	₩706.1b

Price-To-Earnings vs Peers: A001067 is expensive based on its Price-To-Earnings Ratio (20.2x) compared to the peer average (16.9x).

Price to Earnings Ratio vs Industry

How does A001067's PE Ratio compare vs other companies in the KR Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	36.9%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	36.9%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: A001067 is expensive based on its Price-To-Earnings Ratio (20.2x) compared to the KR Pharmaceuticals industry average (15.3x).

Price to Earnings Ratio vs Fair Ratio

What is A001067's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A001067 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	20.2x
Fair PE Ratio	20.5x

Price-To-Earnings vs Fair Ratio: A001067 is good value based on its Price-To-Earnings Ratio (20.2x) compared to the estimated Fair Price-To-Earnings Ratio (20.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.